Equillium, Inc.
EQEquillium, Inc. in brief
Equillium, Inc. is a listed company in the Biotechnology industry, based in La Jolla, California, USA. Its market value was $103 M on 27 October 2026, which makes it the 18,632nd largest listed company in the world and the 3,505th largest in the USA on this site. It employs about 14 people and Bruce D. Steel is its chief executive. Its shares trade under the symbol EQ (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Equillium, Inc.
We are a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. Our primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development.
EQ504 is a preclinical-stage, novel AhR modulator that in multiple translational models has been shown to have a therapeutically beneficial impact inducing anti-inflammatory cells and cytokines while reducing proinflammatory cells and cytokines and improving intestinal tissue barrier function and repair. We initially intend to develop EQ504 for the treatment of ulcerative colitis, or UC, and other gastrointestinal, or GI, diseases with potential indication expansion opportunities for the treatment of inflammatory lung diseases.
From the company's annual report filed with the US SEC: read the report
Equillium, Inc. timeline
- 2018
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 12 October 2018; shares registered for exchange trading on 5 October 2018.
- 2024
- 💰Record revenue of $41 millionFY2024, the highest of the 3 years on record.
Events of Equillium, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,943 (Jan 2020) · #3,517 (Jan 2021) · #4,398 (Jan 2022) · #5,066 (Dec 2022) · #5,093 (Jul 2023) · #4,291 (Jan 2024) · #1,920 (Mar 2026) · #3,244 (Aug 2026) · #3,413 (Oct 2026) · #3,509 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 3.6×
- Free cash flow yield
- -22.2%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -78.3%
- Liabilities / assets
- 10.3%
- Net debt
- $-50M
- Revenue growth
- +13.9%
- R&D / revenue
- 91.1%
- Profit per employee
- $-1.6 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-24M | $-22M | — |
| Dec 2024 | $41M | +13.9% | $-8M | $-8M | -19.6% |
| Dec 2023 | $36M | +128.9% | $-15M | $-13M | -37.0% |
| Dec 2022 | $16M | — | $-62M | $-62M | -396.1% |
| Dec 2021 | — | — | $-38M | $-39M | — |
| Dec 2020 | — | — | $-30M | $-30M | — |
| Dec 2019 | — | — | $-27M | $-26M | — |
| Dec 2018 | — | — | $-9M | $-13M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-23M | $0M | $-23M | $-0.39 | — |
| Dec 2024 | $-19M | $0M | $-19M | $-0.23 | — |
| Dec 2023 | $-22M | $0M | $-22M | $-0.38 | — |
| Dec 2022 | $-9M | $0M | $-9M | $-1.85 | — |
| Dec 2021 | $-32M | $0M | $-32M | $-1.36 | — |
| Dec 2020 | $-25M | $0M | $-25M | $-1.46 | — |
| Dec 2019 | $-23M | $0M | $-23M | $-1.47 | — |
| Dec 2018 | $-8M | $0M | $-8M | $-1.09 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-5M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 12, 20268-KCurrent reportResults of operations
- Oct 26, 20268-KCurrent reportUnregistered share sale · Regulation FD disclosure · Other events
- Oct 5, 20268-KCurrent reportOther events
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 13, 20268-KCurrent reportResults of operations
- May 29, 20268-KCurrent reportShareholder vote
- May 13, 202610-QQuarterly report · period to Mar 2026
- May 13, 20268-KCurrent reportResults of operations
- Apr 15, 2026DEF 14AProxy statement
- Mar 25, 202610-KAnnual report · period to Dec 2025
- Mar 25, 20268-KCurrent reportResults of operations
Official filings of Equillium, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-24 M
- Net income
- $-22 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $32 M
- Total liabilities
- $3 M
- Total equity
- $29 M
As of December-2025
Top 66 institutional investors in Equillium, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Janus Henderson Group Ltd. | 6,494,571 | — | 7.89% | $11 M | Nov 16, 2026 |
| 2 | Aberdeen Group plc | 4,458,351 | +826,692 (+22.76%) | 5.42% | $7 M | Nov 10, 2026 |
| 3 | Decheng Capital LLC | 4,447,308 | 0 (0.00%) | 5.40% | $7 M | Nov 13, 2026 |
| 4 | Woodline Partners LP | 3,500,901 | 0 (0.00%) | 4.25% | $6 M | Nov 16, 2026 |
| 5 | ADAR1 Capital Management, LLC | 3,446,539 | -312,030 (-8.30%) | 4.19% | $6 M | Nov 16, 2026 |
| 6 | Affinity Asset Advisors, LLC | 2,613,954 | -1,486,046 (-36.25%) | 3.18% | $4 M | Nov 13, 2026 |
| 7 | Bank Of America Corp /de/ | 2,600,032 | New | 3.16% | $4 M | Nov 16, 2026 |
| 8 | Ra Capital Management, L.P. | 2,317,741 | -778,595 (-25.15%) | 2.82% | $4 M | Nov 16, 2026 |
| 9 | Vanguard Capital Management LLC | 2,013,744 | +190,932 (+10.47%) | 2.45% | $3 M | Nov 13, 2026 |
| 10 | Eversept Partners, LP | 1,294,446 | -226,378 (-14.89%) | 1.57% | $2 M | Nov 16, 2026 |
| 11 | Marshall Wace, LLP | 750,188 | New | 0.91% | $1 M | Nov 13, 2026 |
| 12 | Citadel Advisors LLC | 592,417 | +492,755 (+494.43%) | 0.72% | $1 M | Nov 16, 2026 |
| 13 | Exome Asset Management LLC | 552,956 | 0 (0.00%) | 0.67% | $1 M | Nov 16, 2026 |
| 14 | Adage Capital Partners GP, L.L.C. | 524,403 | -865,850 (-62.28%) | 0.64% | $1 M | Nov 16, 2026 |
| 15 | DG Capital Management, LLC | 480,166 | +16,770 (+3.62%) | 0.58% | $1 M | Nov 12, 2026 |
| 16 | Geode Capital Management, LLC | 471,555 | +90,380 (+23.71%) | 0.57% | $1 M | Nov 6, 2026 |
| 17 | Renaissance Technologies LLC | 446,691 | -190,926 (-29.94%) | 0.54% | $1 M | Nov 12, 2026 |
| 18 | Squarepoint Ops LLC | 348,123 | New | 0.42% | $1 M | Nov 9, 2026 |
| 19 | Ikarian Capital, LLC | 303,555 | 0 (0.00%) | 0.37% | $0 M | Nov 16, 2026 |
| 20 | Vanguard Fiduciary Trust Co | 301,330 | +110,520 (+57.92%) | 0.37% | $0 M | Nov 13, 2026 |
| 21 | BlackRock, Inc. | 284,704 | -705 (-0.25%) | 0.35% | $0 M | Nov 13, 2026 |
| 22 | Boothbay Fund Management, LLC | 284,330 | 0 (0.00%) | 0.35% | $0 M | Nov 16, 2026 |
| 23 | Susquehanna International Group, LLP | 256,771 | +235,560 (+1110.56%) | 0.31% | $0 M | Nov 16, 2026 |
| 24 | Tudor Investment Corp Et Al | 243,383 | -76,717 (-23.97%) | 0.30% | $0 M | Nov 16, 2026 |
| 25 | State Street Corp | 198,060 | +24,000 (+13.79%) | 0.24% | $0 M | Nov 12, 2026 |
Show all 66: investors 26 to 66
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Acuta Capital Partners, LLC | 183,000 | New | 0.22% | $0 M | Nov 16, 2026 |
| 27 | Two Sigma Investments, LP | 141,482 | -65,371 (-31.60%) | 0.17% | $0 M | Nov 16, 2026 |
| 28 | Integrated Quantitative Investments LLC | 126,010 | New | 0.15% | $0 M | Nov 13, 2026 |
| 29 | Northern Trust Corp | 111,354 | +39,795 (+55.61%) | 0.14% | $0 M | Nov 16, 2026 |
| 30 | Cantor Fitzgerald, L. P. | 109,062 | -109,062 (-50.00%) | 0.13% | $0 M | Nov 16, 2026 |
| 31 | Soleus Capital Management, L.P. | 90,000 | 0 (0.00%) | 0.11% | $0 M | Nov 16, 2026 |
| 32 | Quadrature Capital Ltd | 76,322 | +47,667 (+166.35%) | 0.09% | $0 M | Nov 13, 2026 |
| 33 | American Century Companies Inc | 75,411 | +49,516 (+191.22%) | 0.09% | $0 M | Nov 12, 2026 |
| 34 | China Universal Asset Management Co., Ltd. | 64,000 | +39,000 (+156.00%) | 0.08% | $0 M | Oct 28, 2026 |
| 35 | Jane Street Group, LLC | 57,366 | -37,848 (-39.75%) | 0.07% | $0 M | Nov 12, 2026 |
| 36 | Invesco Ltd. | 53,227 | +16,936 (+46.67%) | 0.06% | $0 M | Nov 12, 2026 |
| 37 | AlphaCore Capital LLC | 52,345 | 0 (0.00%) | 0.06% | $0 M | Nov 4, 2026 |
| 38 | XTX Topco Ltd | 44,883 | +5,620 (+14.31%) | 0.05% | $0 M | Nov 16, 2026 |
| 39 | UBS Group AG | 38,241 | +15,309 (+66.76%) | 0.05% | $0 M | Nov 10, 2026 |
| 40 | Royal Bank Of Canada | 37,197 | New | 0.05% | $0 M | Nov 16, 2026 |
| 41 | Virtu Financial LLC | 36,100 | New | 0.04% | $0 M | Nov 17, 2026 |
| 42 | Barclays PLC | 35,000 | 0 (0.00%) | 0.04% | $0 M | Nov 6, 2026 |
| 43 | Jefferies Financial Group Inc. | 34,100 | 0 (0.00%) | 0.04% | $0 M | Nov 5, 2026 |
| 44 | Schonfeld Strategic Advisors LLC | 33,437 | New | 0.04% | $0 M | Nov 16, 2026 |
| 45 | High Net Worth Advisory Group LLC | 33,230 | -270 (-0.81%) | 0.04% | $0 M | Oct 26, 2026 |
| 46 | Corient Private Wealth LP | 31,936 | New | 0.04% | $0 M | Nov 16, 2026 |
| 47 | Qube Research & Technologies Ltd | 25,695 | New | 0.03% | $0 M | Nov 13, 2026 |
| 48 | Millennium Management LLC | 20,819 | -22,019 (-51.40%) | 0.03% | $0 M | Nov 16, 2026 |
| 49 | Vanguard Global Advisers, LLC | 20,044 | +14,218 (+244.04%) | 0.02% | $0 M | Nov 13, 2026 |
| 50 | Hudson Bay Capital Management LP | 18,260 | New | 0.02% | $0 M | Nov 13, 2026 |
| 51 | Gsa Capital Partners LLP | 17,277 | New | 0.02% | $0 M | Nov 16, 2026 |
| 52 | Chung Wu Investment Group, LLC | 16,500 | 0 (0.00%) | 0.02% | $0 M | Nov 3, 2026 |
| 53 | Focus Partners Wealth | 16,013 | +3,000 (+23.05%) | 0.02% | $0 M | Nov 12, 2026 |
| 54 | Morgan Stanley | 15,842 | -14,045 (-46.99%) | 0.02% | $0 M | Nov 13, 2026 |
| 55 | Coastal Bridge Advisors, LLC | 15,000 | 0 (0.00%) | 0.02% | $0 M | Nov 18, 2026 |
| 56 | Apollon Wealth Management, LLC | 13,875 | 0 (0.00%) | 0.02% | $0 M | Oct 23, 2026 |
| 57 | Raymond James Financial Inc | 13,500 | -61,760 (-82.06%) | 0.02% | $0 M | Nov 12, 2026 |
| 58 | Spark Investment Management LLC | 13,200 | New | 0.02% | $0 M | Nov 13, 2026 |
| 59 | Legato Capital Management LLC | 13,137 | New | 0.02% | $0 M | Nov 10, 2026 |
| 60 | Catalyst Funds Management Pty Ltd | 10,442 | New | 0.01% | $0 M | Nov 12, 2026 |
| 61 | Group One Trading LLC | 2,238 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
| 62 | Wells Fargo & Company/mn | 1,000 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 63 | Jones Financial Companies Lllp | 500 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 64 | SBI Securities Co., Ltd. | 58 | -10 (-14.71%) | 0.00% | $0 M | Oct 22, 2026 |
| 65 | Caitong International Asset Management Co., Ltd | 48 | -186 (-79.49%) | 0.00% | $0 M | Oct 29, 2026 |
| 66 | Citigroup Inc | 13 | -32,682 (-99.96%) | 0.00% | $0 M | Nov 4, 2026 |
Mutual funds holding Equillium, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 abrdn Life Sciences Investorsabrdn Inc. | 3.63 M | $12 M | 4.4% | 1.7% | +8.3% | Jun 30, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 1.40 M | $4 M | 1.7% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 344,489 | $1 M | 0.42% | <0.01% | −0.4% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 164,610 | $0 M | 0.20% | <0.01% | +0.1% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 147,697 | $0 M | 0.18% | 0.03% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 54,720 | $0 M | 0.07% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 47,465 | $0 M | 0.06% | <0.01% | +10% | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 36,683 | $0 M | 0.04% | <0.01% | +15% | May 31, 2026 |
| 🇺🇸 Tiff Multi-Asset FundTIFF Advisory Services, LLC | 31,335 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 24,987 | $0 M | 0.03% | <0.01% | +75% | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 22,500 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 9,860 | $0 M | 0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 10,623 | $0 M | 0.01% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 7,665 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 7,668 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 5,565 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 16 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Equillium, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Christine ZedelmayerSr. Vice President and COO | Option exercise10b5-1 plan | +14,584 | $0.790 | $12 K | 77,170 | Form 4 |
| filed | Stephen ConnellyPresident and CSO | Sell | -30,975 | $2.940 | $91 K | 762,025 | Form 4 |
| filed | Christine ZedelmayerSr. Vice President and COO | Sell10b5-1 plan | -14,584 | $2.930 | $43 K | 62,586 | Form 4 |
| filed | Stephen ConnellyPresident and CSO | Sell | -200,000 | $3.160 | $632 K | 793,000 | Form 4 |
| filed | Penny TomPrincipal Accounting Officer | Option exercise10b5-1 plan | +65,000 | $0.790 | $51 K | 65,000 | Form 4 |
| filed | Penny TomPrincipal Accounting Officer | Sell10b5-1 plan | -65,000 | $2.950 | $192 K | 0 | Form 4 |
| filed | Christine ZedelmayerSr. Vice President and COO | Option exercise10b5-1 plan | +7,292 | $0.730 | $5 K | 69,878 | Form 4 |
| filed | Christine ZedelmayerSr. Vice President and COO | Option exercise10b5-1 plan | +48,512 | $0.770 | $37 K | 118,390 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Equillium, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q4 2023 | Q4 2023 | $0M |
Trading halts
- 2025-08-11 14:13 UTC, code LUDP, resumed 14:18 UTC
- 2025-08-11 13:33 UTC, code LUDP, resumed 13:38 UTC
- 2025-08-01 19:14 UTC, code LUDP, resumed 19:19 UTC
- 2025-08-01 19:06 UTC, code LUDP, resumed 19:11 UTC
Fails to deliver
- : 3,160 shares at $1.25
- : 3,573 shares at $1.42
- : 49,654 shares at $1.45
- : 4,158 shares at $1.89
- : 401 shares at $2.42
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Equillium, Inc. scorecard#
Passes 2 of the 12 checks that could be worked out. Fiscal year 2025; market cap of Oct 27, 2026.
Valuation0 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median3.6×Price to book 3.6× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-22.2%Free cash flow is -22.2% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-0.39 vs -0.23Diluted EPS -0.39 in fiscal 2025 against -0.23 the year before (report's currency).
- ✓Net income higher than five years earlier-$22 M-$22 M in fiscal 2025 against -$30 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$22 MNet income -$22 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-94.0%-94.0% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities10.6×Current ratio 10.59 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year62.1%Diluted shares up 62.1% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Equillium, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | — | 41+13.9%100% | 36+129%100% | 16—100% | — | — | — | — | |
| Research and development | 13−65.7%— | 37+1.1%91.1% | 37−1.4%103% | 38+42.3%238% | 26+36.1%— | 19+9.9%— | 18+257%— | 4.9r4.9—— | |
| General and administrative | 11−9.6%— | 12−12.0%29.0% | 14−21.3%37.6% | 17+51.1%109% | 11+12.2%— | 10+11.9%— | 9.1+147%— | 3.7r3.7—— | |
| Operating expenses | 24−52.1%— | 49−2.5%120% | 51−35.0%140% | 78+106%494% | 38+27.9%— | 30+10.6%— | 27+210%— | 8.6r8.6—— | |
| Operating income | −24—— | −8.3—−20.1% | −15—−40.2% | −62—−394% | −38—— | −30—— | −27—— | −8.6r−8.6—— | |
| Interest and finance income | 0.8−39.7%— | 1.4−40.8%3.4% | 2.3+456%6.5% | 0.4+637%2.7% | 0.1−88.0%— | 0.5−65.8%— | 1.4+309%— | 0.3r0.3—— | |
| Interest expense and finance costs | — | — | 0.5−53.4%1.4% | 1.1−1.9%6.7% | 1.1−2.4%— | 1.1+294%— | 0.3−89.1%— | 2.6r2.6—— | |
| Other non-operating income (expense) | — | — | 1.8—4.9% | −0.4—−2.2% | −1.3—— | −0.3−124%— | 1.1—— | −4.6r−4.6—— | |
| Income before tax | −22—— | −7.7—−18.8% | −13—−35.3% | −62—−396% | −39—— | −30—— | −26—— | −13—— | |
| Income tax | 0−100%— | 0.4−37.8%0.9% | 0.6—1.6% | 0—0.0% | 0—— | 0—— | — | — | |
| Net income including minority interests | −22—— | −8.1—−19.6% | −13—−37.0% | −62—−396% | −39—— | −30—— | −26—— | −13r−13—— | |
| Net income attributable to shareholders | −22—— | −8.1—−19.6% | −13—−37.0% | −62—−396% | −39—— | −30—— | −26—— | −13r−13—— | |
| Earnings per share, basic | -0.39—— | -0.23—— | -0.38—— | -1.85—— | -1.36—— | -1.46—— | -1.47—— | -1.09—— | |
| Earnings per share, diluted | -0.39—— | -0.23—— | -0.38—— | -1.85—— | -1.36—— | -1.46—— | -1.47—— | -1.09—— | |
| Shares, weighted average (basic) | 57+62.1%— | 35+1.8%— | 35+3.0%— | 34+17.1%— | 29—— | — | — | — | |
| Shares, weighted average (diluted) | 57+62.1%— | 35+1.8%— | 35+3.0%— | 34+17.1%— | 29+41.5%— | 20+17.1%— | 17+42.6%— | 12—— | |
| Balance sheet | |||||||||
| Cash and cash equivalents | 30+67.4%95.0% | 18−22.1%70.6% | 23−60.7%45.9% | 59+17.4%75.4% | 50+110%59.0% | 24+81.4%28.1% | 13−53.6%23.8% | 29r29—42.4% | |
| Short-term investments | — | 4.5−74.6%17.5% | 18+48.1%34.9% | 12−60.7%15.2% | 30−47.8%35.5% | 58+45.7%68.1% | 40+6.7%71.9% | 37r37—55.7% | |
| Receivables | — | 0−100%0.0% | 3.7+31.6%7.4% | 2.8—3.6% | 0—0.0% | — | — | — | |
| Other current assets | 0.2−50.1%0.7% | 0.4+82.6%1.7% | 0.2+2838%0.5% | 0.0r2.9−99.7%0.0% | 2.7−11.7%3.1% | 3.0+31.6%3.5% | 2.3+92.9%4.1% | 1.2r1.2—1.8% | |
| Current assets | 31+24.3%97.3% | 25−49.4%97.6% | 49−35.7%97.7% | 77−8.0%97.9% | 83−2.1%97.6% | 85+53.7%99.7% | 55−17.4%99.8% | 67r67—99.9% | |
| Property, plant and equipment | 0.2−37.4%0.5% | 0.3−16.8%1.0% | 0.3−19.4%0.6% | 0.4+65.0%0.5% | 0.2−0.8%0.3% | 0.2+157%0.3% | 0.1+45.3%0.2% | 0.1r0.1—0.1% | |
| Right-of-use (leased) assets | 0.7+80.8%2.1% | 0.4−54.3%1.4% | 0.8−33.2%1.6% | 1.2−27.6%1.5% | 1.6—1.9% | — | — | — | |
| Total assets | 32+24.5%100% | 26−49.3%100% | 51−35.6%100% | 78−8.2%100% | 85−0.0%100% | 85+53.8%100% | 56−17.3%100% | 67r67—100% | |
| Accounts payable | 0.8−71.8%2.4% | 2.7−43.1%10.5% | 4.7+18.4%9.3% | 4.0+225%5.1% | 1.2−55.7%1.4% | 2.8+47.7%3.2% | 1.9+67.4%3.4% | 1.1r1.1—1.7% | |
| Debt due within a year | — | — | — | 5.7+300%7.3% | 1.4−14.3%1.7% | 1.7—2.0% | — | — | |
| Current liabilities | 2.9−53.8%9.2% | 6.4−76.9%24.8% | 28−13.9%54.6% | 32+259%40.9% | 8.9+23.1%10.4% | 7.2+86.6%8.5% | 3.9+91.5%7.0% | 2.0r2.0—3.0% | |
| Long-term debt | — | — | — | 3.2−63.0%4.1% | 8.8+5.7%10.2% | 8.3−14.5%9.7% | 9.7—17.4% | — | |
| Lease liabilities (non-current) | 0.4+90.4%1.1% | 0.2−51.3%0.7% | 0.4−53.4%0.8% | 0.8−33.3%1.1% | 1.2—1.4% | — | — | — | |
| Non-current liabilities | — | — | — | — | — | — | — | 0.2—0.3% | |
| Total liabilities | 3.3−49.7%10.3% | 6.5−76.6%25.6% | 28−39.9%55.3% | 46+146%59.3% | 19+21.4%22.1% | 16+13.8%18.2% | 14+514%24.7% | 2.2r2.2—3.3% | |
| Retained earnings | −216—−678% | −194—−757% | −186—−368% | −172—−220% | −110—−129% | −71—−83.0% | −41—−74.0% | −16r−16—−23.1% | |
| Shareholders' equity | 29+50.0%89.7% | 19−15.6%74.4% | 23−29.3%44.7% | 32−52.0%40.7% | 67−4.8%77.9% | 70+66.9%81.8% | 42−35.6%75.3% | 65r65—96.7% | |
| Total liabilities and equity | 32+24.5%100% | 26−49.3%100% | 51−35.6%100% | 78−8.2%100% | 85−0.0%100% | 85+53.8%100% | 56−17.3%100% | 67r67—100% | |
| Shares outstanding | 61+72.9%— | 36+0.9%— | 35+2.4%— | 34+16.8%— | 29+19.0%— | 25+42.0%— | 17+0.3%— | 17—— | |
| Cash-flow statement | |||||||||
| Depreciation and amortization | — | — | — | 0.1+63.9%0.7% | 0.1+60.0%— | 0.0+95.7%— | 0.0+283%— | 0.0r0.0—— | |
| Share-based compensation | 2.3−38.1%— | 3.8−6.2%9.1% | 4.0−17.4%11.1% | 4.8+9.8%30.7% | 4.4+15.5%— | 3.8+69.5%— | 2.3+410%— | 0.4r0.4—— | |
| Cash from operating activities | −23—— | −19—−46.3% | −22—−60.4% | −8.7—−55.4% | −32—— | −25—— | −23—— | −7.5r−7.5—— | |
| Capital expenditure | −0.0—— | −0.1—−0.2% | −0.1—−0.1% | −0.3—−1.8% | −0.1—— | −0.2—— | −0.1—— | −0.0r−0.0—— | |
| Cash from investing activities | 4.5−67.7%— | 14—33.6% | −4.8−125%−13.2% | 19−31.8%119% | 27—— | −19—— | −2.2—— | −37r−37—— | |
| Shares issued | — | — | — | — | — | — | −0.2—— | — | |
| Shares bought back | — | — | −0.3—−0.7% | — | — | — | — | — | |
| Cash from financing activities | 30+18453%— | 0.2—0.4% | −9.2—−25.6% | −1.2−104%−7.7% | 31−42.4%— | 54+448%— | 9.8−85.2%— | 66r66—— | |
| Change in cash | 12—— | −5.1—−12.5% | −36−511%−99.5% | 8.7−66.9%55.5% | 26+145%— | 11—— | −15−171%— | 21r21—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | — | — | — | — | — | — | — | — | 4.4*−52.3%100% | 12—100% | 14—100% | 11—100% | 9.2*—100% | |
| Research and development | 9.8−47.6%— | 2.5+91.2%— | 2.7−32.7%— | 3.0−49.5%— | 1.5*−79.0%— | 1.3−86.4%— | 4.1−62.2%— | 5.9−39.2%— | 7.3*−20.4%167% | 9.6—78.6% | 11—78.0% | 9.7—91.1% | 9.2*—99.7% | |
| General and administrative | 10−1.3%— | 2.6−21.8%— | 2.4+12.2%— | 2.6−11.1%— | 2.4*+36.7%— | 3.3−0.1%— | 2.1−31.8%— | 2.9−21.2%— | 1.8*−45.0%40.4% | 3.3—27.0% | 3.1—22.7% | 3.7—35.0% | 3.2*—35.0% | |
| Operating expenses | 20−31.2%— | 5.0+10.3%— | 5.2−17.2%— | 5.6−36.8%— | 4.0*−56.4%— | 4.6−64.4%— | 6.2−55.4%— | 8.9−34.2%— | 9.1*−26.8%207% | 13—106% | 14—101% | 13—126% | 12*—135% | |
| Operating income | −20—— | −5.0—— | −5.2—— | −5.6—— | −4.0*—— | −4.6—— | −6.2—— | −8.9—— | −4.7*—−107% | −0.7—−5.6% | −0.1—−0.7% | −2.8—−26.1% | −3.2*—−34.7% | |
| Interest and finance income | 1.6+109%— | 0.5+109%— | 0.5+317%— | 0.3+78.6%— | 0.3*+26.8%— | 0.2−29.0%— | 0.1−67.1%— | 0.2−60.6%— | 0.2*−53.8%5.4% | 0.3—2.7% | 0.4—2.7% | 0.4—4.1% | 0.5*—5.6% | |
| Interest expense and finance costs | — | — | — | — | — | — | — | — | — | — | — | — | 0*—0.0% | |
| Other non-operating income (expense) | — | — | — | — | — | — | — | — | — | — | — | 0.1—0.5% | 0.4*—3.9% | |
| Income before tax | — | — | — | — | — | — | — | — | — | — | — | −2.7—−25.6% | −2.3*—−25.3% | |
| Income tax | — | — | — | — | 0*−100%— | 0—— | 0—— | 0—— | 0.4*+2156%8.2% | 0—0.0% | 0—0.0% | 0—0.0% | 0.0*—0.2% | |
| Net income including minority interests | −18—— | −4.6*—— | −4.7*—— | −5.3—— | −3.8*—— | −4.2*—— | −5.7*−1326%— | −8.7—— | −5.8*—−132% | −0.0*—−0.1% | 0.5*—3.4% | −2.7—−25.6% | −2.3*—−25.4% | |
| Net income attributable to shareholders | −18—— | −4.6—— | −4.7—— | −5.3—— | −3.8*—— | −4.2—— | −5.7−1326%— | −8.7—— | −5.8*—−132% | −0.0—−0.1% | 0.5—3.4% | −2.7—−25.6% | −2.3*—−25.4% | |
| Earnings per share, basic | — | -0.04—— | -0.04—— | -0.06—— | — | -0.06—— | -0.16−1700%— | -0.24—— | — | 0.00—— | 0.01—— | -0.08—— | — | |
| Earnings per share, diluted | — | -0.04—— | -0.04—— | -0.06—— | — | -0.06—— | -0.16−1700%— | -0.24—— | — | 0.00—— | 0.01—— | -0.08—— | — | |
| Shares, weighted average (basic) | 112+71.3%— | 112+71.3%— | 112+213%— | 96+171%— | — | 65+84.4%— | 36+1.2%— | 36+0.9%— | — | 35—— | 35—— | 35—— | — | |
| Shares, weighted average (diluted) | 112+71.3%— | 112+71.3%— | 112+213%— | 96+171%— | — | 65+84.4%— | 36−2.4%— | 36+0.9%— | — | 35—— | 37—— | 35—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 53—95.5% | 53+61.0%95.5% | 57+397%97.4% | 61+323%97.2% | 30+67.4%95.0% | 33+114%96.0% | 11+4.0%92.7% | 15+25.4%86.7% | 18−22.1%70.6% | 15—44.8% | 11—25.8% | 12—26.5% | 23—45.9% | |
| Short-term investments | — | — | — | — | — | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 4.5−74.6%17.5% | 10—30.3% | 22—51.9% | 21—47.5% | 18—34.9% | |
| Receivables | — | — | — | — | — | — | — | — | 0−100%0.0% | 5.0—14.5% | 5.9—13.7% | 5.0—11.6% | 3.7—7.4% | |
| Other current assets | 1.6—2.9% | 1.6+1379%2.9% | 0.8+2095%1.4% | 1.0+2547%1.5% | 0.2−50.1%0.7% | 0.1−71.1%0.3% | 0.0−88.3%0.3% | 0.0−86.9%0.2% | 0.4+82.6%1.7% | 0.4—1.1% | 0.3—0.7% | 0.3—0.6% | 0.2—0.5% | |
| Current assets | 55—98.5% | 55+63.6%98.5% | 58+385%98.8% | 62+284%98.7% | 31+24.3%97.3% | 34−0.2%97.3% | 12−71.5%96.4% | 16−61.8%96.9% | 25−49.4%97.6% | 34—97.6% | 42—97.7% | 42—97.4% | 49—97.7% | |
| Property, plant and equipment | 0.2—0.3% | 0.2−5.7%0.3% | 0.2−6.5%0.3% | 0.2−8.2%0.3% | 0.2−37.4%0.5% | 0.2−40.6%0.5% | 0.2−38.9%1.6% | 0.2−35.5%1.4% | 0.3−16.8%1.0% | 0.3—0.9% | 0.3—0.8% | 0.4—0.8% | 0.3—0.6% | |
| Right-of-use (leased) assets | 0.7—1.2% | 0.7−10.9%1.2% | 0.5+93.1%0.8% | 0.6+102%0.9% | 0.7+80.8%2.1% | 0.8+59.2%2.2% | 0.2−58.4%2.0% | 0.3−59.7%1.7% | 0.4−54.3%1.4% | 0.5—1.4% | 0.6—1.4% | 0.7—1.6% | 0.8—1.6% | |
| Total assets | 56—100% | 56+61.7%100% | 59+373%100% | 63+277%100% | 32+24.5%100% | 35+0.1%100% | 12−71.1%100% | 17−61.6%100% | 26−49.3%100% | 34—100% | 43—100% | 44—100% | 51—100% | |
| Accounts payable | 0.7—1.2% | 0.7−37.4%1.2% | 0.9−82.3%1.4% | 1.3−57.7%2.1% | 0.8−71.8%2.4% | 1.1−70.5%3.1% | 4.8+7.3%38.8% | 3.1+10.1%18.3% | 2.7−43.1%10.5% | 3.7—10.6% | 4.5—10.5% | 2.8—6.4% | 4.7—9.3% | |
| Current liabilities | 2.8—5.1% | 2.8−8.9%5.1% | 2.5−65.7%4.2% | 3.3−44.3%5.3% | 2.9−53.8%9.2% | 3.1−72.0%9.0% | 7.2−64.1%58.3% | 6.0−73.0%35.9% | 6.4−76.9%24.8% | 11—32.1% | 20—47.1% | 22—50.9% | 28—54.6% | |
| Lease liabilities (non-current) | 0.3—0.6% | 0.3−33.8%0.6% | 0.2+57.8%0.3% | 0.3+68.5%0.4% | 0.4+90.4%1.1% | 0.5+112%1.4% | 0.1−57.9%0.9% | 0.1−49.5%0.9% | 0.2−51.3%0.7% | 0.2—0.6% | 0.3—0.6% | 0.3—0.7% | 0.4—0.8% | |
| Total liabilities | 3.1—5.6% | 3.1−12.2%5.6% | 2.7−63.9%4.5% | 3.6−41.5%5.7% | 3.3−49.7%10.3% | 3.6−68.4%10.3% | 7.3−64.1%59.2% | 6.2−72.7%36.8% | 6.5−76.6%25.6% | 11—32.7% | 20—47.7% | 23—51.6% | 28—55.3% | |
| Retained earnings | −231—−414% | −231—−414% | −226—−386% | −222—−351% | −216—−678% | −212—−616% | −208—−1679% | −202—−1210% | −194—−757% | −188—−546% | −188—−439% | −188—−432% | −186—−368% | |
| Shareholders' equity | 53—94.4% | 53+70.3%94.4% | 56+1008%95.5% | 59+462%94.3% | 29+50.0%89.7% | 31+33.5%89.7% | 5.1−77.5%40.8% | 11−49.9%63.2% | 19−15.6%74.4% | 23—67.3% | 22—52.3% | 21—48.4% | 23—44.7% | |
| Total liabilities and equity | 56—100% | 56+61.7%100% | 59+373%100% | 63+277%100% | 32+24.5%100% | 35+0.1%100% | 12−71.1%100% | 17−61.6%100% | 26−49.3%100% | 34—100% | 43—100% | 44—100% | 51—100% | |
| Shares outstanding | 63—— | 63+4.5%— | 63+77.5%— | 63+77.0%— | 61+72.9%— | 61+71.3%— | 36+0.8%— | 36+1.3%— | 36+0.9%— | 35—— | 35—— | 35—— | 35—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 4.0+66.9%— | 1.3+214%— | 1.1+93.3%— | 0.9+49.8%— | 0.7*−10.2%— | 0.4−60.1%— | 0.6−40.9%— | 0.6−36.1%— | 0.8*−21.5%18.7% | 1.0—8.3% | 1.0—6.9% | 1.0—9.1% | 1.0*—11.4% | |
| Cash from operating activities | −15—— | −3.8*—— | −4.1*—— | −4.3—— | −3.1*—— | −8.4*—— | −3.0*−513%— | −8.2—— | −3.3*—−75.1% | −7.7*—−63.0% | 0.7*—5.3% | −8.8—−82.3% | −5.7*—−61.5% | |
| Capital expenditure | −0.1—— | 0*—— | −0.1*—— | −0.0—— | −0.0*—— | 0*—— | 0*—— | −0.0—— | −0.0*—−0.1% | 0*—0.0% | −0.1*—−0.4% | −0.0—−0.2% | −0.0*—−0.4% | |
| Cash from investing activities | −0.1−101%— | 0*—— | −0.1*—— | −0.0−100%— | −0.0*−101%— | 0*−100%— | 0*—— | 4.5—— | 6.0*—137% | 12*—98.7% | −1.4*—−9.8% | −2.8—−26.5% | −5.6*—−60.4% | |
| Shares bought back | — | — | — | — | — | — | — | — | — | — | — | — | 0*—0.0% | |
| Cash from financing activities | 36+18.0%— | −0.0*−100%— | 0.0*—— | 35+38742%— | 0.3*+288%— | 30*—— | −0.0*—— | 0.1—— | 0.1*−7.6%1.7% | 0*—0.0% | — | — | 0.1*—0.9% | |
| Change in cash | 20+14.3%— | −3.8*−118%— | −4.2*—— | 31—— | −2.8*−208%— | 22*+392%— | −3.0*—— | −3.6—— | 2.6*—60.0% | 4.4*—36.1% | −0.5*—−3.7% | −12—−109% | −11*—−121% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Where Equillium, Inc. operates: 2 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 3 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters1 office2 subsidiaries | — |
| 🇦🇺 Australia | 1 subsidiary | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at Equillium, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Bruce D. Steel | $4.3 M | $4.5 M | $2.4 M | $146 |
| 2024Bruce D. Steel | $684 K | $754 K | $513 K | $71 |
| 2023Bruce D. Steel | $1.3 M | $1.0 M | $806 K | $68 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Equillium, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 3 · Auditor changed 2 · Directors and officers 3 · Material agreement 3 · Unregistered share sale 3 · Shareholder vote 2 · Results announced 11
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Unregistered share sale | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Auditor changed | 8-K/A | |
| Auditor changedDirectors and officers | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreementResults announced | 8-K | |
| Delisting notice | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
How Equillium, Inc. compares in Biotechnology
- Market cap$103 M · higher than 36% of 726
- Revenue growth13.9% · higher than 56% of 438
- Price / book3.6× · lower than 41% of 534
- FCF yield-22.2% · higher than 42% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Equillium, Inc.🇺🇸 | $103 M | — | — | +13.9% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 27, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Equillium, Inc.? Verify and update this profile — free
Show Equillium, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.